{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:26:31Z","timestamp":1783031191009,"version":"3.54.6"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40263-024-01111-1","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T06:02:00Z","timestamp":1722664920000},"page":"697-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1209-6073","authenticated-orcid":false,"given":"Hubertus","family":"Himmerich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2991-4757","authenticated-orcid":false,"given":"Jessica","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8879-0865","authenticated-orcid":false,"given":"Susan L.","family":"McElroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"1111_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Press; 2013.","edition":"5"},{"key":"1111_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/YCO.0000000000000818","volume":"35","author":"Y Sil\u00e9n","year":"2022","unstructured":"Sil\u00e9n Y, Keski-Rahkonen A. Worldwide prevalence of DSM-5 eating disorders among young people. Curr Opin Psychiatry. 2022;35:362\u201371. https:\/\/doi.org\/10.1097\/YCO.0000000000000818.","journal-title":"Curr Opin Psychiatry"},{"issue":"1\u20132","key":"1111_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s0165-1781(03)00127-6","volume":"119","author":"LF Fontenelle","year":"2003","unstructured":"Fontenelle LF, V\u013ator Mendlowicz M, de Menezes GB, et al. Psychiatric comorbidity in a Brazilian sample of patients with binge-eating disorder. Psychiatry Res. 2003;119(1\u20132):189\u201394. https:\/\/doi.org\/10.1016\/s0165-1781(03)00127-6.","journal-title":"Psychiatry Res"},{"issue":"3","key":"1111_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/eat.20599","volume":"42","author":"CM Grilo","year":"2009","unstructured":"Grilo CM, White MA, Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord. 2009;42(3):228\u201334. https:\/\/doi.org\/10.1002\/eat.20599.","journal-title":"Int J Eat Disord"},{"issue":"1","key":"1111_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1017\/S1092852921000882","volume":"28","author":"JE Solly","year":"2023","unstructured":"Solly JE, Chamberlain SR, Lust K, et al. Binge-eating disorder in university students: high prevalence and strong link to impulsive and compulsive traits. CNS Spectr. 2023;28(1):61\u20139. https:\/\/doi.org\/10.1017\/S1092852921000882.","journal-title":"CNS Spectr"},{"key":"1111_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.psychres.2019.01.007","volume":"273","author":"A Bahji","year":"2019","unstructured":"Bahji A, Mazhar MN, Hudson CC, et al. Prevalence of substance use disorder comorbidity among individuals with eating disorders: a systematic review and meta-analysis. Psychiatry Res. 2019;273:58\u201366. https:\/\/doi.org\/10.1016\/j.psychres.2019.01.007.","journal-title":"Psychiatry Res"},{"key":"1111_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/erv.2166","volume":"20","author":"C Villarejo","year":"2012","unstructured":"Villarejo C, Fern\u00e1ndez-Aranda F, Jim\u00e9nez-Murcia S, et al. Lifetime obesity. A review of binge eating disorder and obesity review in patients with eating disorders: increasing prevalence, clinical and personality correlates. Eur Eat Disord Rev. 2012;20:250\u20134. https:\/\/doi.org\/10.1002\/erv.2166.","journal-title":"Eur Eat Disord Rev"},{"key":"1111_CR8","volume-title":"Eating disorders and obesity in children and adolescents","author":"J Hebebrand","year":"2019","unstructured":"Hebebrand J, Herpertz-Dahlmann B. Eating disorders and obesity in children and adolescents. St. Louis: Elsevier; 2019."},{"issue":"3","key":"1111_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.biopsych.2006.03.040","volume":"61","author":"JI Hudson","year":"2007","unstructured":"Hudson JI, Hiripi E, Pope HG Jr, et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348\u201358. https:\/\/doi.org\/10.1016\/j.biopsych.2006.03.040.","journal-title":"Biol Psychiatry"},{"key":"1111_CR10","unstructured":"National Institute for Health and Care Excellence (NICE). Eating disorders: Recognition and treatment. (2017). https:\/\/www.nice.org.uk\/guidance\/ng69. Accessed 30 Dec 2023."},{"issue":"10","key":"1111_CR11","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/eat.24023","volume":"56","author":"ST Andersen","year":"2023","unstructured":"Andersen ST, Strandberg-Larsen K, Skovgaard AM, et al. Comparison of prevalence and mental health problems across symptom frequency of self-reported symptoms of binge-eating disorder in a community sample of adolescents. Int J Eat Disord. 2023;56(10):1947\u201360. https:\/\/doi.org\/10.1002\/eat.24023.","journal-title":"Int J Eat Disord"},{"issue":"2","key":"1111_CR12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54366","volume":"16","author":"N Alrahili","year":"2024","unstructured":"Alrahili N, Alghamdi RA, Alqasem AA, et al. Prevalence of eating disorders and comorbidity with depression among adolescents in Saudi Arabia: a cross-sectional study. Cureus. 2024;16(2): e54366. https:\/\/doi.org\/10.7759\/cureus.54366.","journal-title":"Cureus."},{"issue":"1","key":"1111_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40337-022-00726-3","volume":"11","author":"ZARA Abdulla","year":"2023","unstructured":"Abdulla ZARA, Almahmood HO, Alghasra RR, et al. Prevalence and associated factors of binge eating disorder among Bahraini youth and young adults: a cross-sectional study in a self-selected convenience sample. J Eat Disord. 2023;11(1):5. https:\/\/doi.org\/10.1186\/s40337-022-00726-3.","journal-title":"J Eat Disord"},{"key":"1111_CR14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/978-3-662-67685-1_9","volume-title":"Kompendium der Psychiatrischen Pharmakotherapie","author":"H Himmerich","year":"2023","unstructured":"Himmerich H, Benkert O. Medikamente zur Behandlung von Essst\u00f6rungen und Adipositas. In: Bekert O, Hippius H, editors. Kompendium der Psychiatrischen Pharmakotherapie. 14th ed. Berlin: Springer; 2023. p. 803\u201330.","edition":"14"},{"key":"1111_CR15","first-page":"361","volume-title":"Binge eating: Nature, assessment, and treatment","author":"CG Fairburn","year":"1993","unstructured":"Fairburn CG, Marcus MD, Wilson GT. Cognitive-behavioral therapy for binge eating and bulimia nervosa: a comprehensive treatment manual. In: Fairburn CG, Wilson GT, editors. Binge eating: Nature, assessment, and treatment. New York: Guilford Press; 1993. p. 361\u2013404."},{"issue":"8","key":"1111_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/eat.22897","volume":"51","author":"J Linardon","year":"2018","unstructured":"Linardon J. Rates of abstinence following psychological or behavioral treatments for binge-eating disorder: meta-analysis. Int J Eat Disord. 2018;51(8):785\u201397. https:\/\/doi.org\/10.1002\/eat.22897.","journal-title":"Int J Eat Disord"},{"issue":"3","key":"1111_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/eat.20696","volume":"43","author":"S Vocks","year":"2010","unstructured":"Vocks S, Tuschen-Caffier B, Pietrowsky R, et al. Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. Int J Eat Disord. 2010;43(3):205\u201317. https:\/\/doi.org\/10.1002\/eat.20696.","journal-title":"Int J Eat Disord"},{"key":"1111_CR18","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.5113","volume":"6","author":"A Ghaderi","year":"2018","unstructured":"Ghaderi A, Odeberg J, Gustafsson S, et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. PeerJ. 2018;6: e5113. https:\/\/doi.org\/10.7717\/peerj.5113.","journal-title":"PeerJ"},{"key":"1111_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2023.2179663","author":"H Himmerich","year":"2023","unstructured":"Himmerich H, Lewis YD, Conti C, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. World J Biol Psychiatry. 2023. https:\/\/doi.org\/10.1080\/15622975.2023.2179663.","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"1111_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jamapsychiatry.2014.2162","volume":"72","author":"SL McElroy","year":"2015","unstructured":"McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiat. 2015;72(3):235\u201346. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.2162.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"1111_CR21","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/npp.2015.275","volume":"41","author":"SL McElroy","year":"2016","unstructured":"McElroy SL, Hudson J, Ferreira-Cornwell MC, et al. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41(5):1251\u201360. https:\/\/doi.org\/10.1038\/npp.2015.275.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"1111_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/hup.2547","volume":"31","author":"AI Guerdjikova","year":"2016","unstructured":"Guerdjikova AI, Mori N, Blom TJ, et al. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial. Hum Psychopharmacol. 2016;31(5):382\u201391. https:\/\/doi.org\/10.1002\/hup.2547.","journal-title":"Hum Psychopharmacol"},{"issue":"9","key":"1111_CR23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/jamapsychiatry.2017.1889","volume":"74","author":"JI Hudson","year":"2017","unstructured":"Hudson JI, McElroy SL, Ferreira-Cornwell MC, et al. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiat. 2017;74(9):903\u201310. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1889.","journal-title":"JAMA Psychiat"},{"key":"1111_CR24","unstructured":"Shire. Vyvanse. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208510lbl.pdf. Accessed 16 June 2024."},{"issue":"8","key":"1111_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/17512433.2022.2112950","volume":"15","author":"L Carton","year":"2022","unstructured":"Carton L, Icick R, Weibel S, et al. What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion. Expert Rev Clin Pharmacol. 2022;15(8):921\u20135. https:\/\/doi.org\/10.1080\/17512433.2022.2112950.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"1111_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3345\/cep.2021.01466","volume":"67","author":"TH Eom","year":"2024","unstructured":"Eom TH, Kim YH. Clinical practice guidelines for attention-deficit\/hyperactivity disorder: recent updates. Clin Exp Pediatr. 2024;67(1):26\u201334. https:\/\/doi.org\/10.3345\/cep.2021.01466.","journal-title":"Clin Exp Pediatr."},{"issue":"3","key":"1111_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/1098-108x(200011)28:3<325::aid-eat10>3.0.co;2-3","volume":"28","author":"MJ Devlin","year":"2000","unstructured":"Devlin MJ, Goldfein JA, et al. Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy. Int J Eat Disord. 2000;28(3):325\u201332. https:\/\/doi.org\/10.1002\/1098-108x(200011)28:3%3c325::aid-eat10%3e3.0.co;2-3.","journal-title":"Int J Eat Disord"},{"issue":"2","key":"1111_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/eat.23192","volume":"53","author":"DL Safer","year":"2020","unstructured":"Safer DL, Adler S, Dalai SS, et al. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa. Int J Eat Disord. 2020;53(2):266\u201377. https:\/\/doi.org\/10.1002\/eat.23192.","journal-title":"Int J Eat Disord"},{"issue":"5\u20136","key":"1111_CR29","first-page":"17","volume":"15","author":"AI Guerdjikova","year":"2018","unstructured":"Guerdjikova AI, Williams S, Blom TJ, et al. Combination phentermine-topiramate extended release for the treatment of binge eating disorder: an open-label, prospective study. Innov Clin Neurosci. 2018;15(5\u20136):17\u201321.","journal-title":"Innov Clin Neurosci."},{"issue":"2","key":"1111_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/24750573.2017.1409981","volume":"28","author":"A \u00d6nder","year":"2018","unstructured":"\u00d6nder A, Adanir AS. Methylphenidate treatment for binge-eating disorder in 12-year-old boy. Psychiatry Clin Psychopharmacol. 2018;28(2):222\u20133. https:\/\/doi.org\/10.1080\/24750573.2017.1409981.","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"1111_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.psychres.2019.01.066","volume":"273","author":"LC Quilty","year":"2019","unstructured":"Quilty LC, Allen TA, Davis C, et al. A randomized comparison of long acting methylphenidate and cognitive behavioral therapy in the treatment of binge eating disorder. Psychiatry Res. 2019;273:467\u201374. https:\/\/doi.org\/10.1016\/j.psychres.2019.01.066.","journal-title":"Psychiatry Res"},{"issue":"9","key":"1111_CR32","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.biopsych.2006.08.008","volume":"61","author":"SL McElroy","year":"2007","unstructured":"McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039\u201348. https:\/\/doi.org\/10.1016\/j.biopsych.2006.08.008.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"1111_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","volume":"160","author":"SL McElroy","year":"2003","unstructured":"McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(2):255\u201361. https:\/\/doi.org\/10.1176\/appi.ajp.160.2.255.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"1111_CR34","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.4088\/jcp.v68n090","volume":"68","author":"AM Claudino","year":"2007","unstructured":"Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007;68(9):1324\u201332. https:\/\/doi.org\/10.4088\/jcp.v68n090.","journal-title":"J Clin Psychiatry"},{"key":"1111_CR35","unstructured":"Ortho-McNeil-Janssen Pharmaceuticals. Topamax. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020505s014s031s032s037,020844s011s026s027s031lbl.pdf. Accessed 16 June 2024."},{"key":"1111_CR36","unstructured":"US Food and Drug Administration. Statistical review and evaluation: antiepileptic drugs and suicidality. Silver Spring; 2008."},{"issue":"3","key":"1111_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.pain.2012.12.024","volume":"154","author":"A Pereira","year":"2013","unstructured":"Pereira A, Gitlin MJ, Gross RA, et al. Suicidality associated with antiepileptic drugs: implications for the treatment of neuropathic pain and fibromyalgia. Pain. 2013;154(3):345\u20139. https:\/\/doi.org\/10.1016\/j.pain.2012.12.024.","journal-title":"Pain"},{"issue":"13","key":"1111_CR38","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/0333102414529669","volume":"34","author":"M Viana","year":"2014","unstructured":"Viana M, Terreno E, Goadsby PJ, et al. Topiramate for migraine prevention in fertile women: reproductive counseling is warranted. Cephalalgia. 2014;34(13):1097\u20139. https:\/\/doi.org\/10.1177\/0333102414529669.","journal-title":"Cephalalgia"},{"key":"1111_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2023.109953","volume":"120","author":"A Sarayani","year":"2023","unstructured":"Sarayani A, Winterstein A, Cristofoletti R, et al. Real-world effect of a potential drug-drug interaction between topiramate and oral contraceptives on unintended pregnancy outcomes. Contraception. 2023;120: 109953. https:\/\/doi.org\/10.1016\/j.contraception.2023.109953.","journal-title":"Contraception"},{"key":"1111_CR40","first-page":"211","volume":"56","author":"A Rustembegovic","year":"2002","unstructured":"Rustembegovic A, Sofic E, Kroyer G. A pilot study of topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Med Arh. 2002;56:211\u20132.","journal-title":"Med Arh"},{"key":"1111_CR41","first-page":"328","volume":"44","author":"EA Choi","year":"2005","unstructured":"Choi EA, Ki SW, Kim SE, et al. The efficacy and safety of topiramate in the treatment of alcohol withdrawal. J Korean Neuropsychiatr Assoc. 2005;44:328\u201333.","journal-title":"J Korean Neuropsychiatr Assoc"},{"key":"1111_CR42","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1530-0277.2007.00344.x","volume":"31","author":"EM Krupitsky","year":"2007","unstructured":"Krupitsky EM, Rudenko AA, Burakov AM, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res. 2007;31:604\u201311. https:\/\/doi.org\/10.1111\/j.1530-0277.2007.00344.x.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"1111_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1399-5618.2006.00276.x","volume":"8","author":"SF Kushner","year":"2006","unstructured":"Kushner SF, Khan A, Lane R, et al. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 2006;8(1):15\u201327. https:\/\/doi.org\/10.1111\/j.1399-5618.2006.00276.x.","journal-title":"Bipolar Disord"},{"issue":"5","key":"1111_CR44","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1034\/j.1399-5618.2001.30501.x","volume":"3","author":"KN Chengappa","year":"2001","unstructured":"Chengappa KN, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord. 2001;3(5):215\u201332.","journal-title":"Bipolar Disord"},{"key":"1111_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2165\/11589060-000000000-00000","volume":"31","author":"L Citrome","year":"2011","unstructured":"Citrome L, Holt RI, Walker DJ, et al. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011;31:455\u201382. https:\/\/doi.org\/10.2165\/11589060-000000000-00000.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"1111_CR46","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2174\/1871530315666150623092031","volume":"15","author":"H Himmerich","year":"2015","unstructured":"Himmerich H, Minkwitz J, Kirkby KC. Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord Drug Targets. 2015;15(4):252\u201360. https:\/\/doi.org\/10.2174\/1871530315666150623092031.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"4","key":"1111_CR47","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1089\/cap.2022.0098","volume":"33","author":"MP DelBello","year":"2023","unstructured":"DelBello MP, Bruns KM, Bloom T, et al. A double-blind placebo-controlled pilot study of topiramate in manic adolescents treated with olanzapine. J Child Adolesc Psychopharmacol. 2023;33(4):126\u201333. https:\/\/doi.org\/10.1089\/cap.2022.0098.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"1111_CR48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1089\/cap.2009.0042","volume":"19","author":"J Wozniak","year":"2009","unstructured":"Wozniak J, Mick E, Waxmonsky J, Kotarski M, et al. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2009;19(5):539\u201345. https:\/\/doi.org\/10.1089\/cap.2009.0042.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"1111_CR49","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1399-5618.2007.00488.x","volume":"9","author":"SL McElroy","year":"2007","unstructured":"McElroy SL, Frye MA, Altshuler LL, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord. 2007;9(4):426\u201334. https:\/\/doi.org\/10.1111\/j.1399-5618.2007.00488.x.","journal-title":"Bipolar Disord"},{"issue":"11","key":"1111_CR50","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.4088\/jcp.v67n1105","volume":"67","author":"KN Roy Chengappa","year":"2006","unstructured":"Roy Chengappa KN, Schwarzman LK, Hulihan JF, et al. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry. 2006;67(11):1698\u2013706. https:\/\/doi.org\/10.4088\/jcp.v67n1105.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"1111_CR51","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2165\/00003088-200544060-00002","volume":"44","author":"JM Sauer","year":"2005","unstructured":"Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571\u201390. https:\/\/doi.org\/10.2165\/00003088-200544060-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1111_CR52","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4088\/jcp.v68n0306","volume":"68","author":"SL McElroy","year":"2007","unstructured":"McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007;68(3):390\u20138. https:\/\/doi.org\/10.4088\/jcp.v68n0306.","journal-title":"J Clin Psychiatry"},{"key":"1111_CR53","unstructured":"Lilly. Strattera. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021411s029s030lbl.pdf. Accessed 16 June 2024."},{"issue":"12","key":"1111_CR54","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.4088\/jcp.v67n1209","volume":"67","author":"SL McElroy","year":"2006","unstructured":"McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006;67(12):1897\u2013906. https:\/\/doi.org\/10.4088\/jcp.v67n1209.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1111_CR55","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4088\/jcp.v65n0108","volume":"65","author":"SL McElroy","year":"2004","unstructured":"McElroy SL, Kotwal R, Hudson JI, et al. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry. 2004;65(1):50\u20136. https:\/\/doi.org\/10.4088\/jcp.v65n0108.","journal-title":"J Clin Psychiatry"},{"key":"1111_CR56","unstructured":"Azurity Pharmaceuticals. Zonisamide. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214273s000lbl.pdf. Accessed 16 June 2024."},{"key":"1111_CR57","unstructured":"European Medicines Agency: Qsiva - phentermine\/topiramate. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qsiva. Accessed 3 Jan 2023."},{"issue":"12","key":"1111_CR58","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.20220267","volume":"179","author":"CM Grilo","year":"2022","unstructured":"Grilo CM, Lydecker JA, Fineberg SK, et al. Naltrexone-bupropion and behavior therapy, alone and combined, for binge-eating disorder: randomized double-blind placebo-controlled trial. Am J Psychiatry. 2022;179(12):927\u201337. https:\/\/doi.org\/10.1176\/appi.ajp.20220267.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"1111_CR59","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/oby.23898","volume":"31","author":"CM Grilo","year":"2023","unstructured":"Grilo CM, Lydecker JA, Jastreboff AM, et al. Naltrexone\/bupropion for binge-eating disorder: a randomized, double-blind, placebo-controlled trial. Obesity (Silver Spring). 2023;31(11):2762\u201373. https:\/\/doi.org\/10.1002\/oby.23898.","journal-title":"Obesity (Silver Spring)"},{"key":"1111_CR60","unstructured":"Orexigen Therapeutics. Contrave. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/200063s000lbl.pdf. Accessed 16 June 2024."},{"issue":"4","key":"1111_CR61","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4088\/JCP.12m08071","volume":"74","author":"MA White","year":"2013","unstructured":"White MA, Grilo CM. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(4):400\u20136. https:\/\/doi.org\/10.4088\/JCP.12m08071.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1111_CR62","first-page":"143","volume":"19","author":"MA Marrazzi","year":"1995","unstructured":"Marrazzi MA, Markham KM, Kinzie J, et al. Binge eating disorder: response to naltrexone. Int J Obes Relat Metab Disord. 1995;19(2):143\u20135.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"2","key":"1111_CR63","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/obr.12625","volume":"19","author":"A Qasim","year":"2018","unstructured":"Qasim A, Turcotte M, de Souza RJ, et al. On the origin of obesity: identifying the biological, environmental and cultural drivers of genetic risk among human populations. Obes Rev. 2018;19(2):121\u201349. https:\/\/doi.org\/10.1111\/obr.12625.","journal-title":"Obes Rev"},{"issue":"9","key":"1111_CR64","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.biopsych.2012.11.020","volume":"73","author":"RC Kessler","year":"2013","unstructured":"Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73(9):904\u201314. https:\/\/doi.org\/10.1016\/j.biopsych.2012.11.020.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1111_CR65","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2012.113905","volume":"309","author":"KM Flegal","year":"2013","unstructured":"Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71\u201382. https:\/\/doi.org\/10.1001\/jama.2012.113905.","journal-title":"JAMA"},{"issue":"5","key":"1111_CR66","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","volume":"163","author":"E Grunvald","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198\u2013225. https:\/\/doi.org\/10.1053\/j.gastro.2022.08.045.","journal-title":"Gastroenterology"},{"issue":"4","key":"1111_CR67","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2042098613489721","volume":"4","author":"BM Cheung","year":"2013","unstructured":"Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf. 2013;4(4):171\u201381. https:\/\/doi.org\/10.1177\/2042098613489721.","journal-title":"Ther Adv Drug Saf."},{"issue":"20","key":"1111_CR68","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity management in adults: a review. JAMA. 2023;330(20):2000\u201315. https:\/\/doi.org\/10.1001\/jama.2023.19897.","journal-title":"JAMA"},{"key":"1111_CR69","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58:7370\u201380. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00726.","journal-title":"J Med Chem"},{"key":"1111_CR70","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide. Physiol Rev. 2007;87:1409\u201339.","journal-title":"Physiol Rev"},{"key":"1111_CR71","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","volume":"84","author":"DJ Drucker","year":"1987","unstructured":"Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA. 1987;84:3434\u20138. https:\/\/doi.org\/10.1073\/pnas.84.10.3434.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1111_CR72","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cobeha.2016.02.005","volume":"9","author":"MR Hayes","year":"2016","unstructured":"Hayes MR, Schmidt HD. GLP-1 influences food and drug reward. Curr Opin Behav Sci. 2016;9:66\u201370. https:\/\/doi.org\/10.1016\/j.cobeha.2016.02.005.","journal-title":"Curr Opin Behav Sci"},{"issue":"3","key":"1111_CR73","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/JCP.0000000000001869","volume":"44","author":"H Himmerich","year":"2024","unstructured":"Himmerich H, McElroy SL. Glucagon-like peptide 1 receptor agonists in psychiatry. J Clin Psychopharmacol. 2024;44(3):207\u201310. https:\/\/doi.org\/10.1097\/JCP.0000000000001869.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"1111_CR74","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1080\/17512433.2022.2130760","volume":"15","author":"Q Lin","year":"2022","unstructured":"Lin Q, Xue Y, Zou H, et al. Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol. 2022;15(12):1461\u20139. https:\/\/doi.org\/10.1080\/17512433.2022.2130760.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1111_CR75","unstructured":"Novo Nordisk. Victoza. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022341s027lbl.pdf. Accessed 16 June 2024."},{"issue":"3","key":"1111_CR76","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.orcp.2015.03.005","volume":"9","author":"SA Robert","year":"2015","unstructured":"Robert SA, Rohana AG, Shah SA, et al. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide\u2014a pilot study. Obes Res Clin Pract. 2015;9(3):301\u20134. https:\/\/doi.org\/10.1016\/j.orcp.2015.03.005.","journal-title":"Obes Res Clin Pract"},{"issue":"11","key":"1111_CR77","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"key":"1111_CR78","unstructured":"Novo Nordisk. Ozempic. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf. Accessed 16 June 2024."},{"key":"1111_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17856","author":"C Lupianez-Merly","year":"2024","unstructured":"Lupianez-Merly C, Dilmaghani S, Vosoughi K, et al. Pharmacologic management of obesity: updates on approved medications, indications and risks. Aliment Pharmacol Ther. 2024. https:\/\/doi.org\/10.1111\/apt.17856.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1111_CR80","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s12325-022-02394-w","volume":"40","author":"PW Moore","year":"2023","unstructured":"Moore PW, Malone K, VanValkenburg D, et al. GLP-1 agonists for weight loss: pharmacology and clinical implications. Adv Ther. 2023;40(3):723\u201342. https:\/\/doi.org\/10.1007\/s12325-022-02394-w.","journal-title":"Adv Ther"},{"issue":"7","key":"1111_CR81","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1055\/a-1844-1176","volume":"54","author":"X Guo","year":"2022","unstructured":"Guo X, Zhou Z, Lyu X, et al. The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis. Horm Metab Res. 2022;54(7):458\u201371. https:\/\/doi.org\/10.1055\/a-1844-1176.","journal-title":"Horm Metab Res"},{"key":"1111_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100080","volume":"7","author":"J Richards","year":"2023","unstructured":"Richards J, Bang N, Ratliff EL, et al. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study. Obes Pillars. 2023;7: 100080. https:\/\/doi.org\/10.1016\/j.obpill.2023.100080.","journal-title":"Obes Pillars."},{"issue":"3","key":"1111_CR83","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"6","key":"1111_CR84","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al. Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial. N Engl J Med. 2023;389(6):514\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2301972.","journal-title":"N Engl J Med"},{"key":"1111_CR85","unstructured":"Vivus. Qsymia. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022580s000lbl.pdf. Accessed 16 June 2024."},{"issue":"9774","key":"1111_CR86","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(11)60205-5.","journal-title":"Lancet"},{"issue":"2","key":"1111_CR87","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330\u201342. https:\/\/doi.org\/10.1038\/oby.2011.330.","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"1111_CR88","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297\u2013308. https:\/\/doi.org\/10.3945\/ajcn.111.024927.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"1111_CR89","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/dom.13910","volume":"22","author":"DS Hsia","year":"2020","unstructured":"Hsia DS, Gosselin NH, Williams J, et al. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine\/topiramate in adolescents with obesity. Diabetes Obes Metab. 2020;22(4):480\u201391. https:\/\/doi.org\/10.1111\/dom.13910.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1111_CR90","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/oby.20584","volume":"21","author":"LJ Aronne","year":"2013","unstructured":"Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163\u201371. https:\/\/doi.org\/10.1002\/oby.20584.","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"1111_CR91","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/ijo.2013.145","volume":"38","author":"GJ Wang","year":"2014","unstructured":"Wang GJ, Tomasi D, Volkow ND, et al. Effect of combined naltrexone and bupropion therapy on the brain\u2019s reactivity to food cues. Int J Obes (Lond). 2014;38(5):682\u20138. https:\/\/doi.org\/10.1038\/ijo.2013.145.","journal-title":"Int J Obes (Lond)"},{"issue":"9741","key":"1111_CR92","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595\u2013605. https:\/\/doi.org\/10.1016\/S0140-6736(10)60888-4.","journal-title":"Lancet"},{"issue":"5","key":"1111_CR93","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935\u201343. https:\/\/doi.org\/10.1002\/oby.20309.","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"1111_CR94","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/acer.15118","volume":"47","author":"HR Kranzler","year":"2023","unstructured":"Kranzler HR, Hartwell EE. Medications for treating alcohol use disorder: a narrative review. Alcohol Clin Exp Res (Hoboken). 2023;47(7):1224\u201337. https:\/\/doi.org\/10.1111\/acer.15118.","journal-title":"Alcohol Clin Exp Res (Hoboken)."},{"issue":"11","key":"1111_CR95","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13326","volume":"22","author":"NN Ahmad","year":"2021","unstructured":"Ahmad NN, Robinson S, Kennedy-Martin T, et al. Clinical outcomes associated with anti-obesity medications in real-world practice: a systematic literature review. Obes Rev. 2021;22(11): e13326. https:\/\/doi.org\/10.1111\/obr.13326.","journal-title":"Obes Rev"},{"issue":"10","key":"1111_CR96","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/oby.2005.208","volume":"13","author":"A Golay","year":"2005","unstructured":"Golay A, Laurent-Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res. 2005;13(10):1701\u20138. https:\/\/doi.org\/10.1038\/oby.2005.208.","journal-title":"Obes Res"},{"issue":"10","key":"1111_CR97","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.biopsych.2005.03.001","volume":"57","author":"CM Grilo","year":"2005","unstructured":"Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2005;57(10):1193\u2013201. https:\/\/doi.org\/10.1016\/j.biopsych.2005.03.001.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"1111_CR98","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.brat.2013.01.002","volume":"51","author":"CM Grilo","year":"2013","unstructured":"Grilo CM, White MA. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino\/as. Behav Res Ther. 2013;51(3):167\u201375. https:\/\/doi.org\/10.1016\/j.brat.2013.01.002.","journal-title":"Behav Res Ther"},{"issue":"6","key":"1111_CR99","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/jcp.0b013e31815a8872","volume":"27","author":"M Kluge","year":"2007","unstructured":"Kluge M, Schuld A, Himmerich H, et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol. 2007;27(6):662\u20136. https:\/\/doi.org\/10.1097\/jcp.0b013e31815a8872.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1111_CR100","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/s0022-3956(03)00018-9","volume":"37","author":"U Zimmermann","year":"2003","unstructured":"Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res. 2003;37(3):193\u2013220. https:\/\/doi.org\/10.1016\/s0022-3956(03)00018-9.","journal-title":"J Psychiatr Res"},{"key":"1111_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107667","volume":"217","author":"H Himmerich","year":"2021","unstructured":"Himmerich H, Kan C, Au K, et al. Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences. Pharmacol Ther. 2021;217: 107667. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107667.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"1111_CR102","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061476","volume":"12","author":"S Kulkarni","year":"2022","unstructured":"Kulkarni S, Durham H, Glover L, et al. Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis. BMJ Open. 2022;12(12): e061476. https:\/\/doi.org\/10.1136\/bmjopen-2022-061476.","journal-title":"BMJ Open"},{"key":"1111_CR103","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fphar.2020.00481","volume":"11","author":"O Patsalos","year":"2020","unstructured":"Patsalos O, Dalton B, Leppanen J, et al. Impact of TNF-\u03b1 inhibitors on body weight and BMI: a systematic review and meta-analysis. Front Pharmacol. 2020;11:481. https:\/\/doi.org\/10.3389\/fphar.2020.00481.","journal-title":"Front Pharmacol"},{"issue":"17","key":"1111_CR104","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.3390\/ijms21176290","volume":"21","author":"O Patsalos","year":"2020","unstructured":"Patsalos O, Dalton B, Himmerich H. Effects of IL-6 signaling pathway inhibition on weight and BMI: a systematic review and meta-analysis. Int J Mol Sci. 2020;21(17):6290. https:\/\/doi.org\/10.3390\/ijms21176290.","journal-title":"Int J Mol Sci"},{"key":"1111_CR105","unstructured":"Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2024."},{"issue":"2","key":"1111_CR106","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.psychres.2015.09.008","volume":"230","author":"S Ulfvebrand","year":"2015","unstructured":"Ulfvebrand S, Birgeg\u00e5rd A, Norring C, et al. Psychiatric comorbidity in women and men with eating disorders results from a large clinical database. Psychiatry Res. 2015;230(2):294\u20139. https:\/\/doi.org\/10.1016\/j.psychres.2015.09.008.","journal-title":"Psychiatry Res"},{"issue":"3","key":"1111_CR107","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/13651501.2017.1306082","volume":"21","author":"M Bauer","year":"2017","unstructured":"Bauer M, Severus E, M\u00f6ller HJ, et al. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. Int J Psychiatry Clin Pract. 2017;21(3):166\u201376. https:\/\/doi.org\/10.1080\/13651501.2017.1306082.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"2","key":"1111_CR108","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/eat.20946","volume":"45","author":"AI Guerdjikova","year":"2012","unstructured":"Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial. Int J Eat Disord. 2012;45(2):281\u20139. https:\/\/doi.org\/10.1002\/eat.20946.","journal-title":"Int J Eat Disord"},{"key":"1111_CR109","unstructured":"Lilly. Cymbalta. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021427s049lbl.pdf. Accessed 16 June 2024."},{"issue":"9","key":"1111_CR110","doi-asserted-by":"publisher","first-page":"802","DOI":"10.4088\/jcp.v63n0909","volume":"63","author":"S Malhotra","year":"2002","unstructured":"Malhotra S, King KH, Welge JA, et al. Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J Clin Psychiatry. 2002;63(9):802\u20136. https:\/\/doi.org\/10.4088\/jcp.v63n0909.","journal-title":"J Clin Psychiatry"},{"key":"1111_CR111","unstructured":"Pfizer. Effexor. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020699s107lbl.pdf. Accessed 16 June 2024."},{"issue":"7","key":"1111_CR112","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4088\/jcp.v64n0711","volume":"64","author":"SL McElroy","year":"2003","unstructured":"McElroy SL, Hudson JI, Malhotra S, et al. Citalopram in the treatment of binge eating disorder: a placebo-controlled trial. J Clin Psychiatry. 2003;64(7):807\u201313. https:\/\/doi.org\/10.4088\/jcp.v64n0711.","journal-title":"J Clin Psychiatry"},{"key":"1111_CR113","unstructured":"Allergan. Celexa. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020822s041lbl.pdf. Accessed 16 June 2024."},{"issue":"1","key":"1111_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hup.899","volume":"23","author":"AI Guerdjikova","year":"2008","unstructured":"Guerdjikova AI, McElroy SL, Kotwal R, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol. 2008;23(1):1\u201311. https:\/\/doi.org\/10.1002\/hup.899.","journal-title":"Hum Psychopharmacol"},{"issue":"6","key":"1111_CR115","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1176\/appi.ajp.157.6.1004","volume":"157","author":"SL McElroy","year":"2000","unstructured":"McElroy SL, Casuto LS, Nelson EB, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry. 2000;157(6):1004\u20136. https:\/\/doi.org\/10.1176\/appi.ajp.157.6.1004.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1111_CR116","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/hup.758","volume":"21","author":"P Leombruni","year":"2006","unstructured":"Leombruni P, Piero A, Brustolin A, et al. A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters. Hum Psychopharmacol. 2006;21(3):181\u20138. https:\/\/doi.org\/10.1002\/hup.758.","journal-title":"Hum Psychopharmacol"},{"key":"1111_CR117","unstructured":"Pfizer. Zoloft. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019839s74s86s87_20990s35s44s45lbl.pdf. Accessed 16 June 2024."},{"key":"1111_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.949823","volume":"13","author":"H Duan","year":"2022","unstructured":"Duan H, Zhu L, Li M, et al. Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: a network meta-analysis. Front Pharmacol. 2022;13: 949823. https:\/\/doi.org\/10.3389\/fphar.2022.949823.","journal-title":"Front Pharmacol"},{"issue":"11","key":"1111_CR119","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.4088\/jcp.v63n1113","volume":"63","author":"LM Arnold","year":"2002","unstructured":"Arnold LM, McElroy SL, Hudson JI, et al. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry. 2002;63(11):1028\u201333. https:\/\/doi.org\/10.4088\/jcp.v63n1113.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"1111_CR120","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/ajp.147.7.876","volume":"147","author":"MD Marcus","year":"1990","unstructured":"Marcus MD, Wing RR, Ewing L, et al. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 1990;147(7):876\u201381. https:\/\/doi.org\/10.1176\/ajp.147.7.876.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"1111_CR121","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/oby.2007.203","volume":"15","author":"MJ Devlin","year":"2007","unstructured":"Devlin MJ, Goldfein JA, Petkova E, et al. Cognitive behavioral therapy and fluoxetine for binge eating disorder: two-year follow-up. Obesity. 2007;15(7):1702\u20139. https:\/\/doi.org\/10.1038\/oby.2007.203.","journal-title":"Obesity"},{"issue":"3","key":"1111_CR122","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.biopsych.2004.11.002","volume":"57","author":"CM Grilo","year":"2005","unstructured":"Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 2005;57(3):301\u20139. https:\/\/doi.org\/10.1016\/j.biopsych.2004.11.002.","journal-title":"Biol Psychiatry"},{"key":"1111_CR123","unstructured":"Lilly. Prozac. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018936s108lbl.pdf. Accessed 16 June 2024."},{"key":"1111_CR124","unstructured":"Gartlehner G, Hansen RA, Morgan LC, et al. Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. Rockville, MD; Agency for Healthcare Research and Quality (US). Rockville (MD): Agency for Healthcare Research and Quality (US); 2011. Report No. 12-EHC012-EF."},{"key":"1111_CR125","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11126-011-9192-0","volume":"83","author":"C Calandra","year":"2012","unstructured":"Calandra C, Russo RG, Luca M. Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study. Psychiatr Q. 2012;83:177\u201385. https:\/\/doi.org\/10.1007\/s11126-011-9192-0.","journal-title":"Psychiatr Q"},{"key":"1111_CR126","unstructured":"GlaxoSmithKline. Wellbutrin. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018644s043lbl.pdf. Accessed 16 June 2024."},{"issue":"4","key":"1111_CR127","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.rpsm.2014.12.001","volume":"8","author":"EM \u00c1lvarez Ruiz","year":"2015","unstructured":"\u00c1lvarez Ruiz EM, Guti\u00e9rrez-Rojas L. Comorbidity of bipolar disorder and eating disorders. Rev Psiquiatr Salud Ment. 2015;8(4):232\u201341. https:\/\/doi.org\/10.1016\/j.rpsm.2014.12.001.","journal-title":"Rev Psiquiatr Salud Ment."},{"issue":"2","key":"1111_CR128","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3109\/15622970903555881","volume":"11","author":"H Grunze","year":"2010","unstructured":"Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81\u2013109. https:\/\/doi.org\/10.3109\/15622970903555881.","journal-title":"World J Biol Psychiatry."},{"issue":"1","key":"1111_CR129","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/15622975.2017.1384850","volume":"19","author":"H Grunze","year":"2018","unstructured":"Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry. 2018;19(1):2\u201358. https:\/\/doi.org\/10.1080\/15622975.2017.1384850.","journal-title":"World J Biol Psychiatry."},{"issue":"Suppl 1","key":"1111_CR130","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/0019-5545.196974","volume":"59","author":"N Shah","year":"2017","unstructured":"Shah N, Grover S, Rao GP. Clinical practice guidelines for management of bipolar disorder. Indian J Psychiatry. 2017;59(Suppl 1):51\u201366. https:\/\/doi.org\/10.4103\/0019-5545.196974.","journal-title":"Indian J Psychiatry."},{"key":"1111_CR131","unstructured":"National Institute for Health and Care Excellence (NICE). Bipolar disorder: assessment and management. Published: 24 September 2014 Last updated: 21 December 2023. https:\/\/www.nice.org.uk\/guidance\/cg185\/chapter\/Recommendations. Accessed 22 Feb 2024."},{"key":"1111_CR132","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pbb.2014.02.004","volume":"123","author":"A Can","year":"2014","unstructured":"Can A, Schulze TG, Gould TD. Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav. 2014;123:3\u201316. https:\/\/doi.org\/10.1016\/j.pbb.2014.02.004.","journal-title":"Pharmacol Biochem Behav"},{"key":"1111_CR133","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-56015-1","volume-title":"Neuropsychopharmacotherapy","author":"H Himmerich","year":"2022","unstructured":"Himmerich H, Hamilton A. Mood stabilizers: side effects, contraindications, and interactions. In: Riederer P, Laux G, Nagatsu T, Le W, Riederer C, editors. Neuropsychopharmacotherapy. Berlin: Springer; 2022. https:\/\/doi.org\/10.1007\/978-3-319-56015-1."},{"key":"1111_CR134","unstructured":"West-Ward Pharmaceuticals. Lithium. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/017812s033,018421s032,018558s027lbl.pdf. Accessed 16 June 2024."},{"issue":"1","key":"1111_CR135","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","volume":"181","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, Kwan ATH, Rosenblat JD, et al. Psychotropic drug-related weight gain and its treatment. Am J Psychiatry. 2024;181(1):26\u201338. https:\/\/doi.org\/10.1176\/appi.ajp.20230922.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1111_CR136","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40345-023-00313-8","volume":"11","author":"W Greil","year":"2023","unstructured":"Greil W, de Bardeci M, M\u00fcller-Oerlinghausen B, et al. Controversies regarding lithium-associated weight gain: case-control study of real-world drug safety data. Int J Bipolar Disord. 2023;11(1):34. https:\/\/doi.org\/10.1186\/s40345-023-00313-8.","journal-title":"Int J Bipolar Disord."},{"key":"1111_CR137","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jad.2018.09.025","volume":"266","author":"SR Yaramala","year":"2020","unstructured":"Yaramala SR, McElroy SL, Geske J, et al. The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: findings from the bipolar CHOICE study. J Affect Disord. 2020;266:772\u201381. https:\/\/doi.org\/10.1016\/j.jad.2018.09.025.","journal-title":"J Affect Disord"},{"issue":"Suppl 2","key":"1111_CR138","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1111\/j.1528-1167.2008.01792.x","volume":"36","author":"JA Messenheimer","year":"1995","unstructured":"Messenheimer JA. Lamotrigine. Epilepsia. 1995;36(Suppl 2):S87-94. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01792.x.","journal-title":"Epilepsia"},{"issue":"2","key":"1111_CR139","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1399-5618.2006.00432.x","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97\u2013170. https:\/\/doi.org\/10.1111\/j.1399-5618.2006.00432.x.","journal-title":"Bipolar Disord"},{"issue":"3","key":"1111_CR140","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/YIC.0b013e328329c7b5","volume":"24","author":"AI Guerdjikova","year":"2009","unstructured":"Guerdjikova AI, McElroy SL, Welge JA, et al. Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol. 2009;24(3):150\u20138. https:\/\/doi.org\/10.1097\/YIC.0b013e328329c7b5.","journal-title":"Int Clin Psychopharmacol"},{"key":"1111_CR141","unstructured":"GlaxoSmithKline. Lamictal. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020241s045s051lbl.pdf. Accessed 16 June 2024."},{"issue":"8","key":"1111_CR142","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","volume":"15","author":"EW Tuplin","year":"2017","unstructured":"Tuplin EW, Holahan MR. Aripiprazole, a drug that displays partial agonism and functional selectivity. Curr Neuropharmacol. 2017;15(8):1192\u2013207. https:\/\/doi.org\/10.2174\/1570159X15666170413115754.","journal-title":"Curr Neuropharmacol"},{"key":"1111_CR143","unstructured":"Otsuka. Abilify. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021436s038,021713s030,021729s022,021866s023lbl.pdf. Accessed 16 June 2024."},{"issue":"2","key":"1111_CR144","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","volume":"171","author":"A Loebel","year":"2014","unstructured":"Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160\u20138. https:\/\/doi.org\/10.1176\/appi.ajp.2013.13070984.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1111_CR145","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","volume":"171","author":"A Loebel","year":"2014","unstructured":"Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169\u201377. https:\/\/doi.org\/10.1176\/appi.ajp.2013.13070985.","journal-title":"Am J Psychiatry"},{"issue":"1\u20132","key":"1111_CR146","first-page":"21","volume":"12","author":"R Bawa","year":"2015","unstructured":"Bawa R, Scarff JR. Lurasidone: a new treatment option for bipolar depression\u2014a review. Innov Clin Neurosci. 2015;12(1\u20132):21\u20133.","journal-title":"Innov Clin Neurosci."},{"key":"1111_CR147","unstructured":"Dainippon Sumitomo Pharma. Latuda. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/200603lbls10s11.pdf. Accessed 16 June 2024."},{"issue":"12","key":"1111_CR148","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3390\/brainsci13121641","volume":"13","author":"G Longo","year":"2023","unstructured":"Longo G, Cicolini A, Orsolini L, et al. The novel antipsychotic lumateperone (Iti-007) in the treatment of schizophrenia: a systematic review. Brain Sci. 2023;13(12):1641. https:\/\/doi.org\/10.3390\/brainsci13121641.","journal-title":"Brain Sci"},{"issue":"12","key":"1111_CR149","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","volume":"178","author":"JR Calabrese","year":"2021","unstructured":"Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178(12):1098\u2013106. https:\/\/doi.org\/10.1176\/appi.ajp.2021.20091339.","journal-title":"Am J Psychiatry"},{"key":"1111_CR150","unstructured":"Intra-Cellular Therapies. Caplyta. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209500s000lbl.pdf. Accessed 16 June 2024."},{"issue":"Suppl","key":"1111_CR151","first-page":"5","volume":"55","author":"JE Leysen","year":"1994","unstructured":"Leysen JE, Janssen PM, Megens AA, et al. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994;55(Suppl):5\u201312.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1111_CR152","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00115-009-2870-6","volume":"81","author":"T Veselinovi\u0107","year":"2010","unstructured":"Veselinovi\u0107 T, Himmerich H. Antihistaminergic antipsychotics cause weight gain. Nervenarzt. 2010;81(3):329\u201334. https:\/\/doi.org\/10.1007\/s00115-009-2870-6.","journal-title":"Nervenarzt"},{"issue":"4","key":"1111_CR153","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/cap.2008.0120","volume":"19","author":"Y Roke","year":"2009","unstructured":"Roke Y, van Harten PN, Boot AM, et al. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol. 2009;19(4):403\u201314. https:\/\/doi.org\/10.1089\/cap.2008.0120.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1111_CR154","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/656370","volume":"2014","author":"N Divac","year":"2014","unstructured":"Divac N, Prostran M, Jakovcevski I, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014: 656370. https:\/\/doi.org\/10.1155\/2014\/656370.","journal-title":"Biomed Res Int"},{"key":"1111_CR155","unstructured":"Janssen. Risperdal. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020272s056,020588s044,021346s033,021444s03lbl.pdf. Accessed 16 June 2024."},{"issue":"5","key":"1111_CR156","first-page":"281","volume":"10","author":"A S\u00fcmegi","year":"2008","unstructured":"S\u00fcmegi A. Quetiapin in bipolar disorders. Neuropsychopharmacol Hung. 2008;10(5):281\u201391.","journal-title":"Neuropsychopharmacol Hung"},{"issue":"5","key":"1111_CR157","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/17460441.2017.1304378","volume":"12","author":"AS Miranda","year":"2017","unstructured":"Miranda AS, Moreira FA, Teixeira AL. The preclinical discovery and development of quetiapine for the treatment of mania and depression. Expert Opin Drug Discov. 2017;12(5):525\u201335. https:\/\/doi.org\/10.1080\/17460441.2017.1304378.","journal-title":"Expert Opin Drug Discov"},{"key":"1111_CR158","unstructured":"AstraZeneca Pharmaceuticals. Seroquel. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020639s061lbl.pdf. Accessed 16 June 2024."},{"issue":"2","key":"1111_CR159","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/15622975.2022.2086295","volume":"24","author":"B Bandelow","year":"2023","unstructured":"Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders\u2014version 3. Part I: anxiety disorders. World J Biol Psychiatry. 2023;24(2):79\u2013117. https:\/\/doi.org\/10.1080\/15622975.2022.2086295.","journal-title":"World J Biol Psychiatry."},{"issue":"2","key":"1111_CR160","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/15622975.2022.2086296","volume":"24","author":"B Bandelow","year":"2023","unstructured":"Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders\u2014version 3. Part II: OCD and PTSD. World J Biol Psychiatry. 2023;24(2):118\u201334. https:\/\/doi.org\/10.1080\/15622975.2022.2086296.","journal-title":"World J Biol Psychiatry."},{"key":"1111_CR161","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eurpsy.2011.11.003","volume":"28","author":"B Dell'osso","year":"2013","unstructured":"Dell\u2019osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013;28:7\u201320. https:\/\/doi.org\/10.1016\/j.eurpsy.2011.11.003.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"1111_CR162","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/15622975.2016.1246752","volume":"18","author":"M Soyka","year":"2017","unstructured":"Soyka M, Kranzler HR, Hesselbrock V, et al. Guidelines for biological treatment of substance use and related disorders, part 1: alcoholism, first revision. World J Biol Psychiatry. 2017;18(2):86\u2013119. https:\/\/doi.org\/10.1080\/15622975.2016.1246752.","journal-title":"World J Biol Psychiatry."},{"issue":"10","key":"1111_CR163","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1111\/add.15853","volume":"117","author":"A Bahji","year":"2022","unstructured":"Bahji A, Bach P, Danilewitz M, et al. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. Addiction. 2022;117(10):2591\u2013601. https:\/\/doi.org\/10.1111\/add.15853.","journal-title":"Addiction"},{"issue":"2","key":"1111_CR164","doi-asserted-by":"publisher","first-page":"CD008544","DOI":"10.1002\/14651858.CD008544.pub2","volume":"2014","author":"PP Pani","year":"2014","unstructured":"Pani PP, Trogu E, Pacini M, et al. Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev. 2014;2014(2):CD008544. https:\/\/doi.org\/10.1002\/14651858.CD008544.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1111_CR165","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001867.pub3","author":"S R\u00f6sner","year":"2010","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010. https:\/\/doi.org\/10.1002\/14651858.CD001867.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1111_CR166","unstructured":"Duramed Pharmaceuticals. Revia. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018932s017lbl.pdf. Accessed 16 June 2024."},{"issue":"11","key":"1111_CR167","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1111\/add.13457","volume":"111","author":"M Solmi","year":"2016","unstructured":"Solmi M, Veronese N, Sergi G, et al. The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. Addiction. 2016;111(11):1914\u201322. https:\/\/doi.org\/10.1111\/add.13457.","journal-title":"Addiction"},{"issue":"10","key":"1111_CR168","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.arbres.2023.07.024","volume":"59","author":"C R\u00e1bade-Castedo","year":"2023","unstructured":"R\u00e1bade-Castedo C, de Granda-Orive JI, Riesco-Miranda JA, et al. Clinical Practice Guideline of Spanish Society of Pneumology and Thoracic Surgery (SEPAR) on pharmacological treatment of tobacco dependence 2023. Arch Bronconeumol. 2023;59(10):651\u201361. https:\/\/doi.org\/10.1016\/j.arbres.2023.07.024.","journal-title":"Arch Bronconeumol"},{"issue":"3","key":"1111_CR169","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/10401230600801077","volume":"18","author":"LA Adler","year":"2006","unstructured":"Adler LA, Spencer T, Faraone SV, et al. Validity of pilot adult ADHD self- report scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry. 2006;18(3):145\u20138. https:\/\/doi.org\/10.1080\/10401230600801077.","journal-title":"Ann Clin Psychiatry"},{"issue":"4","key":"1111_CR170","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/09540261.2019.1571995","volume":"31","author":"H Himmerich","year":"2019","unstructured":"Himmerich H, Bentley J, Lichtblau N, et al. Facets of shared decision-making on drug treatment for adults with an eating disorder. Int Rev Psychiatry. 2019;31(4):332\u201346. https:\/\/doi.org\/10.1080\/09540261.2019.1571995.","journal-title":"Int Rev Psychiatry"},{"key":"1111_CR171","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0037-1600991","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9\u201362. https:\/\/doi.org\/10.1055\/s-0037-1600991.","journal-title":"Pharmacopsychiatry"},{"key":"1111_CR172","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed 16 June 2024."},{"issue":"10445","key":"1111_CR173","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/S0140-6736(24)00874-2","volume":"403","author":"H Himmerich","year":"2024","unstructured":"Himmerich H, Keeler JL, Davies HL, et al. The evolving profile of eating disorders and their treatment in a changing and globalised world. Lancet. 2024;403(10445):2671\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(24)00874-2.","journal-title":"Lancet"},{"issue":"3","key":"1111_CR174","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1017\/S0029665122000994","volume":"81","author":"J Treasure","year":"2022","unstructured":"Treasure J, Bektas S, Mutwalli H, et al. Novel approaches to tackling emotional loss of control of eating across the weight spectrum. Proc Nutr Soc. 2022;81(3):255\u201363. https:\/\/doi.org\/10.1017\/S0029665122000994.","journal-title":"Proc Nutr Soc"},{"issue":"4","key":"1111_CR175","doi-asserted-by":"publisher","first-page":"348","DOI":"10.21614\/chirurgia.2023.v.118.i.4.p.348","volume":"118","author":"RP Soroceanu","year":"2023","unstructured":"Soroceanu RP, Soroceanu A, Timofte DV, et al. From pleasure to pathology: understanding the neural basis of food addiction in the context of obesity. Chirurgia (Bucur). 2023;118(4):348\u201357. https:\/\/doi.org\/10.21614\/chirurgia.2023.v.118.i.4.p.348.","journal-title":"Chirurgia (Bucur)."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01111-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01111-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01111-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T07:24:58Z","timestamp":1723447498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01111-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":175,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1111"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01111-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"15 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.H. has received salary support from the National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) at the South London and Maudsley NHS Foundation Trust (SLaM) and King\u2019s College London (KCL).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"H.H. is the chief investigator for an NIHR HTA-funded feasibility study testing olanzapine in young patients with anorexia nervosa (AN) and the principal investigator of a COMPASS Pathways-funded and -sponsored proof-of-concept study testing psilocybin in AN. J.B. declares no conflict of interest. S.L.M. is or has been a consultant to or member of the scientific advisory boards of Allergan, Bracket (now Signant Health), F. Hoffmann-La Roche Ltd., Idorsia, Intra-Cellular Therapies, Mitsubishi Tanabe Pharma America, Myriad, Novo Nordisk, Otsuka, Shire (now Takeda), and Sunovion. She has been or is a principal or coinvestigator on studies sponsored by Allergan, Brainsway, Idorsia, Jazz, Marriott Foundation, Myriad, the National Institute of Mental Health, Novo Nordisk, Shire (now Takeda), and Sunovion. She is also an inventor on US patent no. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent\u2019s assignee, University of Cincinnati, Cincinnati, Ohio, has received payments from Johnson & Johnson, which has exclusive rights under the patent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"H.H. is responsible for the design of the work; acquisition, analysis, and interpretation of data; drafting the work; and revisions. J.B. is responsible for the design of the work; acquisition, analysis, and interpretation of data; drafting the work; and revisions. S.L.M. is responsible for the design of the work; acquisition, analysis, and interpretation of data; drafting the work; and revisions. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}